Short Wave
What It's Like Taking Alzheimer's Drugs
Mar 3, 2025
Jon Hamilton, NPR Science Correspondent, dives into the promising but complex world of newly approved Alzheimer's drugs. He shares personal stories from patients navigating the challenges of the disease. One woman’s experience in a clinical trial sheds light on the emotional toll alongside potential hope. They discuss the drugs' effectiveness, risks, and how they target beta amyloid plaques. The podcast beautifully intertwines science with human experiences, reminding us of the delicate balance between medical advancements and individual journeys.
12:51
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- The FDA-approved Alzheimer's drugs can moderately slow mental decline but their effectiveness varies significantly among individuals.
- Patient experiences reveal that while some may find temporary cognitive stability, many face the sobering reality of diminishing benefits over time.
Deep dives
Introduction to Alzheimer's Treatments
Two drugs have gained FDA approval for treating early-stage Alzheimer's disease, targeting the removal of beta amyloid plaques in the brain. Both drugs require intravenous infusion and come with a significant cost of over $25,000 per year. While effective in clearing amyloid, the drugs only moderately slow the progression of symptoms, showcasing benefits that can vary widely among individuals. This uncertainty often drives patients to try these medications despite the risks involved, including potential severe side effects like brain swelling.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
